This double-blind, placebo-controlled crossover trial (n=16) investigates whether pretreatment with memantine can prevent the memory impairment typically caused by MDMA in recreational users.
Randomised design not specified in registry; double-blind, placebo-controlled four-way crossover in recreational MDMA users. Subjects receive memantine 20 mg or placebo, and 2 hours later receive MDMA 75 mg or placebo, with at least a one-week washout between sessions (4 sessions total).
Primary outcome is memory performance measured immediately after each treatment using verbal and prospective memory tests. Secondary measures include event-related potentials (P300) and perceptual/speech analyses.
Four-way, double-blind crossover with memantine/placebo pretreatment and MDMA/placebo challenge.
Memantine 20 mg PO given ~2 hours before challenge.
Single oral MDMA 75 mg.